Melatonina
Anno: 1999
-
Riferimento:Environ Health Perspect. 1999 Feb;107 Suppl 1:145-54. Review.Azione della melatonina:Melatonin-breast cancer and EMF-breast cancer hypotheses.Target:Electromagnetic fields (EMF).
-
Riferimento:FASEB J. 1999 May;13(8):857-68.Azione della melatonina:Melatonin interferes with the activation of estrogen receptor by estradiol.Target:Estrogen receptor DNA.
-
Riferimento:J Pineal Res. 1999 Jan;26(1):1-8.Azione della melatonina:Melatonin may have a role in the regulation of peripheral blood cell counts.Target:Serum melatonin/circadian rhythms.
-
Riferimento:J Pineal Res. 1999 Mar;26(2):65-100. Review.Azione della melatonina:Decreased melatonin production leads to increased risk of breast cancer.Target:Light at night/electromagnetic fields (EMF).
-
Riferimento:Biol Signals Recept. 1999 Jan-Apr;8(1-2):75-8.Azione della melatonina:Melatonin may influence the proliferation of tumor cells via RZR/ROR receptors.Target:CGP 52608 ligand for RZR/ROR receptors.
-
Riferimento:Oncology. 1999;56(2):169-76.Azione della melatonina:Human breast cancer patients showed a decline in circulating melatonin levels.Target:Tryptophan 2,3-dioxygenase (TDO).
-
Riferimento:BMJ. 1999 Jan 23;318(7178):224-8.Azione della melatonina:Di Bella multitherapy did not show sufficient efficacy in patients with advanced cancer to warrant further clinical testing.Target:386 patients with advanced cancer were enrolled.
-
Riferimento:BMJ. 1999 Jan 23;318(7178):224-8.Azione della melatonina:Di Bella multitherapy did not show sufficient efficacy in patients with advanced cancer to warrant further clinical testing.Target:Di Bella multitherapy.
-
Riferimento:Neuro Endocrinol Lett. 1999;20(3-4):139-144.Azione della melatonina:Possible therapeutic significance of melatonin in neoplastic disease.Target:Alterations in melatonin concentrations
-
Riferimento:Eur J Cancer. 1999 Nov;35(12):1688-92.Azione della melatonina:MLT (20 mg/day orally) may enhance the efficacy of chemotherapy and reduce its toxicity. Tumour response rate: 42/124 CT + MLT versus 19/126 CT (5-FU plus folinic acid) only.Target:Counteract chemotherapy toxicity.